Celltrion Reveals Data As It Rolls Out Higher-Strength Adalimumab

Presents One-Year Data From Phase III Trial For Yuflyma Rival To Humira

As it begins to roll out its Yuflyma higher-strength adalimumab biosimilar in Europe, Celltrion has reported positive one-year data from a Phase III trial for the 100mg/ml Humira rival.

Spain Europe Map Scratch Off
Spain is one of the initial launch markets for Yuflyma • Source: Alamy

Celltrion has revealed fresh one-year Phase III trial data for its Yuflyma (adalimumab) biosimilar rival to Humira as it begins the process of rolling out the product – the world’s first approved higher-strength adalimumab biosimilar – in various markets in Europe.

As it announced its recent first-quarter results, Celltrion indicated that it planned to have launched Yuflyma in more than 70%...

More from Biosimilars

More from Products

Alchem Fined Over Buscopan API Cartel

 
• By 

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

Apotex Follows Biocon With Canadian Biosimilar Aflibercept Launch

 
• By 

Apotex is marking a “key milestone,” introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016 in its native Canada, with the approval and launch of a biosimilar to Eylea 2mg.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By 

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.